Ashley Yoo

Ashley Yoo

Auto-generated profile, based on publicly available information

Ashley Yoo

Internal Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
EEEstelle Everett
Estelle Everett
BKBrian Kane
Brian Kane
AYAshley Yoo
Ashley Yoo
ADAdrian Dobs
Adrian Dobs
NMNestoras Mathioudakis
Nestoras Mathioudakis
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

16 March 2021 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
ARAna Ruiz-Saenz
Ana Ruiz-Saenz
FZFarima Zahedi
Farima Zahedi
EPElliott Peterson
Elliott Peterson
AYAshley Yoo
Ashley Yoo
CDCourtney A. Dreyer
Courtney A. Dreyer
MMMark M. Moasser
Mark M. Moasser
The Src family kinases (SFK) are homologs of retroviral oncogenes, earning them the label of proto-oncogenes. Their functions are influenced by positive and negative regulatory tyrosine phosphorylation events and inhibitory and activating intramolecular and extramolecular interactions. This regulation is disrupted in their viral oncogene counterparts. However, in contrast to most other proto-oncogenes, the genetic alteration of these genes does not seem to occur in human tumors and how and whether their functions are altered in human cancers remain to be determined. To look for proteomic-level alterations, we took a more granular look at the activation states of SFKs based on their two known regulatory tyrosine phosphorylations, but found no significant differences in their activity states when comparing immortalized epithelial cells with cancer cells. SFKs are known to have other less well-studied phosphorylations, particularly within their unstructured N-terminal unique domains (UD), although their role in cancers has not been explored. In comparing panels of epithelial cells with cancer cells, we found a decrease in S17 phosphorylation in the UD of Src in cancer cells. Dephosphorylated S17 favors the dimerization of Src that is mediated through the UD and suggests increased Src dimerization in cancers. These data highlight the important role of the UD of Src and suggest that a deeper understanding of proteomic-level alterations of the unstructured UD of SFKs may provide considerable insights into how SFKs are deregulated in cancers. Implications: This work highlights the role of the N-terminal UD of Src kinases in regulating their signaling functions and possibly in their deregulation in human cancers.

8 April 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
AYAshley Yoo
Ashley Yoo
JCJoyce Chen
Joyce Chen
VSVivek Sarma
Vivek Sarma
CACherinne Arundel
Cherinne Arundel
A man in his 70s with a history of unresectable hepatocellular carcinoma (HCC) treated with nivolumab presented with a blistering rash 14 months after nivolumab initiation. Biopsies and direct immunofluorescence confirmed the diagnosis of bullous pemphigoid (BP). BP is an autoimmune skin disorder in which autoantibodies bind to the dermal–epidermal junction. It is a rare sequela of programmed cell death protein-1 (PD-1) inhibitors that can develop after treatment initiation and typically resolve soon after discontinuation. Most cases are reported in melanoma and non-small cell lung cancers, and rarely in HCC irrespective of the timing of onset. We describe a rare presentation of remote BP with PD-1 inhibitor use in HCC. PD-1 inhibitor-induced BP is a rare cutaneous immune-related adverse event, and this case highlights the variability in onset and chronicity.

1 January 2026 in BMJ Open Quality
Verified
Journal Article
Open access
AYAshley Yoo
Ashley Yoo
NCNikitha Cherayil
Nikitha Cherayil
RRRose Sanchez Rosado
Rose Sanchez Rosado
ARAnna Rubin
Anna Rubin
The American Diabetes Association has declared continuous glucose monitoring (CGM) use to be the standard of care in patients with diabetes mellitus (DM) on insulin. While primary care providers (PCPs) manage most patients with DM, the adoption of CGMs in the primary care setting remains significantly lower than in endocrinology practices. PCPs have reported education, insurance authorisation and challenges of a PCP environment as significant barriers to CGM use. Our project sought to increase CGM prescriptions at our academic primary care clinic by creating tools to address these barriers. This is a single-centre quality improvement study at our academic primary care practice with the aim to increase CGM prescriptions in our patients with DM prescribed insulin, excluding patients seen by the endocrinology department. Three interventions were introduced over a 10-month period: (1) an educational pamphlet detailing insurance coverage, ordering and documentation requirements, (2) electronic health record tools to aid in ordering and documentation and (3) a didactic session focused on CGM data interpretation. The number of CGM prescriptions beginning August 2024 was reported monthly. Provider comfort with CGM prescription and data interpretation was assessed using a Likert scale of 1–5 (5 being the most comfortable). Following all three interventions, CGM prescriptions increased by 6.6%. On survey, providers reported improvements in correctly prescribing CGMs and comfort in interpreting CGM data. Referrals to endocrinology for type 2 DM also decreased by 25.3%. Despite known benefits of use in DM care, CGMs are underused in the primary care setting. Provider education and tools led to an increase in CGM prescriptions and improved PCP comfort with CGM use. These interventions demonstrate an effective way to address key barriers to CGM use in primary care.

3 April 2023
Verified
Other
Open access
ARAna Ruiz-Saenz
Ana Ruiz-Saenz
FZFarima Zahedi
Farima Zahedi
EPElliott Peterson
Elliott Peterson
AYAshley Yoo
Ashley Yoo
CDCourtney A. Dreyer
Courtney A. Dreyer
MMMark M. Moasser
Mark M. Moasser

3 April 2023
Verified
Other
Open access
ARAna Ruiz-Saenz
Ana Ruiz-Saenz
FZFarima Zahedi
Farima Zahedi
EPElliott Peterson
Elliott Peterson
AYAshley Yoo
Ashley Yoo
CDCourtney A. Dreyer
Courtney A. Dreyer
MMMark M. Moasser
Mark M. Moasser
The Src family kinases (SFK) are homologs of retroviral oncogenes, earning them the label of proto-oncogenes. Their functions are influenced by positive and negative regulatory tyrosine phosphorylation events and inhibitory and activating intramolecular and extramolecular interactions. This regulation is disrupted in their viral oncogene counterparts. However, in contrast to most other proto-oncogenes, the genetic alteration of these genes does not seem to occur in human tumors and how and whether their functions are altered in human cancers remain to be determined. To look for proteomic-level alterations, we took a more granular look at the activation states of SFKs based on their two known regulatory tyrosine phosphorylations, but found no significant differences in their activity states when comparing immortalized epithelial cells with cancer cells. SFKs are known to have other less well-studied phosphorylations, particularly within their unstructured N-terminal unique domains (UD), although their role in cancers has not been explored. In comparing panels of epithelial cells with cancer cells, we found a decrease in S17 phosphorylation in the UD of Src in cancer cells. Dephosphorylated S17 favors the dimerization of Src that is mediated through the UD and suggests increased Src dimerization in cancers. These data highlight the important role of the UD of Src and suggest that a deeper understanding of proteomic-level alterations of the unstructured UD of SFKs may provide considerable insights into how SFKs are deregulated in cancers.Implications:This work highlights the role of the N-terminal UD of Src kinases in regulating their signaling functions and possibly in their deregulation in human cancers.